The taming of the Wild West of social media has begun, with the FTC reinforcing its role as sheriff. To keep the peace and help drugmakers and other industries ride through the new digital territories unscathed, the FTC updated its 13-year-old ".com Disclosures" guidance. Read More
The FDA published a notice in the Federal Register about the public workshop called "Drug Development for Chronic Fatigue Syndrome [CFS] and Myalgic Encephalomyelitis [ME]," slated for April 25-26 in Bethesda, Md. Read More
Now that its underwriter has exercised an option to purchase an additional $1.45 million in company stock, Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., is well situated to move ahead with its pipeline of compounded drug formulations based on its Accudel drug delivery technology, including Impracor, a Phase III pain candidate designed to deliver ketoprofen through the skin directly to underlying tissues. Read More
• Oxford Gene Technology, of Oxford, UK, was granted a license by the Institute of Cancer Research, London, to further develop and commercialize a new panel of diagnostic and prognostic microRNA biomarkers for prostate cancer. Terms were not disclosed. Read More
• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., closed its underwritten offering of about 27.4 million shares of common stock and warrants for up to 13.7 million additional shares at 55 cents apiece. Gross proceeds were $15.1 million. Read More
• Takeda Pharmaceutical Co., of Tokyo, and the Scripps Research Institute announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases. Read More
• BioLineRx Ltd., of Jerusalem, said it received approval from French regulators to start a Phase I/II trial of BL-8020, an oral, interferon-free treatment for hepatitis C virus (HCV). Read More
